Longevity: Vilon (Lys-Glu, KE-Peptid) – Khavinson's Thymic Dipeptide and the Chromatin Question

74 PubMed hits, no Western Phase 2/3 trial, no FDA/EMA/BfArM approval – and yet a SIRT1 mechanism freshly characterised in 2023. What a 274-Da dipeptide from St Petersburg teaches us about epigenetics, thymic involution, and the peptide bioregulator hypothesis.

In October 2023 Khavinson, Linkova and colleagues at the St Petersburg Institute of Bioregulation and Gerontology published an in vitro study in Advances in Gerontology that delivers the most precise molecular mechanism for Vilon to date (Khavinson VK et al., Adv Gerontol 2023;36(3):302-312, PMID 37782636): the Lys-Glu dipeptide – internally designated KE peptide – increases SIRT1 gene expression 6-fold and SIRT1 protein 8.2-fold in young human mesenchymal stem cells, while in aged cells it reduces PARP1 mRNA 2.1-fold (protein 5.3-fold) and PARP2 mRNA 2.1-fold (protein 4.7-fold). Molecular modelling indicates that KE binds the dsDNA sequence GCGG in the promoter regions of SIRT1, PARP1 and PARP2 – a direct gene-regulatory mechanism that is remarkably concrete for a two-amino-acid peptide.

Vilon is among the best-characterised members of the Russian peptide bioregulator family. The catch: the clinical evidence, and the majority of the preclinical evidence, comes from that institute and its Georgian collaboration partners. There are no Western Phase 2/3 RCTs. Vilon is used clinically in Russia and is not approved in the EU, USA, Germany, Switzerland or Canada. This article traces the data with precision: substantive, but not independently replicated.

Background: The Khavinson School of Peptide Bioregulators

Vladimir Kh. Khavinson (b. 1946) heads the St Petersburg Institute of Bioregulation and Gerontology. The central hypothesis: aging is accompanied by a decline in the production of short regulatory peptides, which in the young organism are generated by the turnover of tissue-specific proteins. Exogenous substitution reactivates tissue-specific function.

Pharmacological operationalisation proceeded in three stages:

1. Cytomedins (1970s–1980s): polypeptide fractions from thymus, pineal gland, cerebral cortex, liver. Thymalin and Epithalamin were approved in Russia as adjuvants in oncology and paediatrics – observational clinical studies in 266 patients reported a 2- to 4-fold reduction in mortality and cancer incidence.
2. Identification of short peptides (1990s): Vilon (Lys-Glu) from thymus, Epithalon (AEDG) from pineal, Cortagen (AEDP) from cerebral cortex, Livagen (KEDA) from liver.
3. Synthesis and pharmacological characterisation (from 2000 onwards).

Vilon is, in this logic, the thymic analogue. Thymalin (a thymic polypeptide complex) is approved in Russia as an immune adjuvant in oncology and paediatrics; Vilon is the defined, synthetic, fully reproducible version of the same concept.

What is Vilon at the Molecular Level?

Vilon is a linear dipeptide of L-lysine and L-glutamic acid:

• Sequence: H-Lys-Glu-OH (L-lysyl-L-glutamic acid)
• Formula: C₁₁H₂₁N₃O₅
• Molecular weight: 274.3 Da – one of the smallest therapeutic peptides known
• Synthesis: standard solid-phase peptide synthesis (SPPS) – inexpensive, scalable
• Administration: intramuscular, subcutaneous or oral – in animal studies administered per os via drinking water (Khavinson VKh et al., Bull Exp Biol Med 2002, PMID 12420071)
• Stability: as a native dipeptide, partial hydrolysis by gastrointestinal exopeptidases is expected; nevertheless, systemic effects have been observed after oral dosing in published rat studies.

For comparison: Epithalon (AEDG) 390 Da, Cortagen (AEDP) 430 Da, Livagen (KEDA) 445 Da, Pinealon (EDR) 418 Da. Vilon is by some margin the smallest molecule in the family.

Mechanism of Action – Six Layers of Evidence

The mechanistic evidence for Vilon is, for such a small peptide, multilayered. Six layers – in descending order of methodological strength:

1. Direct DNA Binding in Promoters (Most Modern Data Point, 2023)

The strongest mechanistic data come from Khavinson et al. (PMID 37782636). In young human MSCs, KE increased SIRT1 mRNA 6-fold and protein 8.2-fold. In aged MSCs, KE reduced PARP1 mRNA 2.1-fold (protein 5.3-fold) and PARP2 mRNA 2.1-fold (protein 4.7-fold). Both effects are biologically plausible: SIRT1 is an NAD⁺-dependent deacetylase central to longevity and DNA repair; PARP1/2 consume NAD⁺ and competitively inhibit SIRT1. KE normalises the SIRT1/PARP balance in favour of SIRT1 – a plausible longevity mechanism.

Molecular modelling additionally indicates that KE binds the dsDNA sequence GCGG in the promoter regions of SIRT1, PARP1 and PARP2 – a direct gene-regulatory mechanism that does not require a classical membrane receptor. Caveat: in silico modelling plus cellular mRNA/protein data, not a direct DNA-binding assay (ChIP, EMSA). The mechanism remains a working hypothesis awaiting independent biochemical confirmation.

2. Chromatin Epigenetics in Lymphocytes of Elderly Humans

The Georgian group around Tamara Lezhava has documented Vilon's chromatin activity in cultured lymphocytes of 75-88-year-old donors:

• 2004 (Lezhava T et al., Biogerontology 5(2):73-79, PMID 15105581): Vilon induces deheterochromatinisation of facultative heterochromatin and reactivates ribosomal genes. In vitro epigenetics on human primary material.
• 2006 (Lezhava T et al., Georgian Med News 2006;(133):111-115, PMID 16705247): Vilon reactivates ribosomal genes without decondensing pericentromeric heterochromatin – a specific signature.
• 2023 (Lezhava T et al., Georgian Med News 2023;(335):79-83, PMID 37042594): Updated data confirm selective deheterochromatinisation of facultative heterochromatin.

Biological significance: heterochromatin accumulation is a recognised hallmark of aging. Selective loosening without pericentromeric decondensation (chromosome stability preserved) would be exactly the desired profile – epigenetic reactivation without genomic instability.

3. Tissue Specificity: Thymic Cytomedin Logic

A central pillar of the Khavinson hypothesis: peptide bioregulators act tissue-specifically – Cortagen on cerebral cortex, Livagen on liver, Epithalon on pineal, Vilon on thymus. Khavinson tested all four peptides on explant cultures from thymus, liver, brain and kidney. Only Vilon significantly stimulated the growth of thymic explants (Khavinson VK, Bull Exp Biol Med 2001 Aug;132(2):807-808, PMID 11713572) – an elegant, indirect confirmation of the cytomedin hypothesis.

4. Direct Mitogenic Effect on Thymocytes

With aging the thymus involutes – the organ is replaced by adipose tissue, naive T-cell output falls. In thymocyte co-culture with Vilon, Raikhlin et al. observed increased expression of argyrophilic proteins in nucleolar organiser regions (AgNOR) – a marker of ribosomal RNA synthesis and cell proliferation. Vilon transformed thymocytes directly into proliferating blast cells (Raikhlin NT et al., Bull Exp Biol Med 2004 Jun;137(6):588-591, PMID 15455093). Interestingly, Epithalon showed the opposite effect – a further piece of evidence for the tissue-specific logic.

5. Inhibition of Apoptosis in Lymphocytes

In splenic lymphocyte cultures, Vilon inhibited apoptosis more strongly than Epithalon (Khavinson VK, Kvetnoii IM, Bull Exp Biol Med 2000 Dec;130(12):1175-1176, PMID 11276315) – another consistent mechanistic building block for preserved immune competence in old age.

6. Gene-Expression Footprint in the Heart (Transcriptomic Signature)

A microarray study (Anisimov SV et al., Bull Exp Biol Med 2002 Mar;133(3):293-299, PMID 12360356) examined 15,247 cDNA clones in the mouse heart. Vilon alone modulated 36 clones more than 2-fold; in combination with Epithalon 157 clones (peak induction 6.13-fold). Vilon and Epithalon act differently, not additively.

Preclinical and Clinical Evidence in Detail

Lifespan Study in CBA Mice (Khavinson 2000, PMID 11140587)

The methodologically strongest preclinical lifespan study: female CBA mice received subcutaneous Vilon from the 6th month of life in chronic administration. Findings:

• Physical activity ↑ (open-field test)
• Endurance ↑ (swim-to-exhaustion test)
• Extended lifespan vs. placebo
• Spontaneous tumours ↓
• Safety: no chronic toxicity signals with lifelong administration

The CBA mouse is a classical gerontology model with well-characterised age trajectories. The effects are consistent with the bioregulator hypothesis, but – as with all mouse lifespan data – only of limited direct translatability to humans.

Anticarcinogenic Data – with an Honest Negative Finding

The oncology data are mixed – and that is precisely what makes the case credible:

• Positive (Pliss GB et al., Bull Exp Biol Med 2001 Jun;131(6):558-560, PMID 11586406): in a nitrosamine-induced bladder-cancer model in rats, Vilon reduced tumour incidence from 75.5% to 56%. Preneoplastic lesions fell roughly 2-fold – a substantial chemopreventive effect.
• Negative (Anisimov VN et al., Int J Cancer 2002 Sep 1;101(1):7-10, PMID 12209581): in HER-2/neu transgenic mice, Vilon increased tumour incidence; Epithalon reduced it. Anisimov et al. concluded that the anticancer effect is context-dependent. This negative finding is essential – it rules out any blanket anti-cancer claim.

Renal and Gastrointestinal Effects

Two further organ systems with documented Vilon activity:

• Kidney (Gavrisheva NA et al., Bull Exp Biol Med 2005 Jan;139(1):24-26, PMID 16142267): in rats with chronic renal failure, Vilon reduced TGF-β and normalised mesenteric microvascular permeability – a homeostatic effect in the early phase of renal insufficiency.
• Gut (Khavinson VKh et al., Bull Exp Biol Med 2002, PMID 12420071 and PMID 12660839): oral Vilon in old rats improved glucose and glycine transport in the small intestine and increased maltase and alkaline phosphatase in the intestinal epithelium – a trophic effect on the aging gut mucosa, relevant to the malabsorption commonly seen in old age.

Clinical Data in Humans – Elderly Type-1 Diabetics

The methodologically strongest human study (Kuznik BI et al., Adv Gerontol 2007;20(2):106-115, PMID 18306698): elderly type-1 diabetics received Vilon in addition to standard therapy:

• Coagulation homeostasis ↑: antithrombin III, protein C, fibrinolysis activity all rose significantly
• Insulin dose ↓
• T-lymphocyte subpopulations normalised
• IgA levels normalised

The study is small, not randomised-controlled in the Western sense, and published in a Russian-language journal (English abstract). But it is real human data – not an animal model. For a peptide with no Western Phase 2/3 trials, that is a substantive data point.

Immunomodulation – Vilon Analogue R-1

A thymic cell-culture study with Vilon and its analogue R-1 (Sevostianova NN et al., Bull Exp Biol Med 2013 Feb;154(4):562-565, PMID 23486604) showed that R-1 stimulates the differentiation of CD5⁺ precursors into mature CD4⁺ T-helper cells and CD8⁺ cytotoxic T cells – direct evidence for the thymus-specific T-cell-differentiation effect. Vilon itself had a weaker but consistent effect.

Comparison Table: The Peptide Bioregulator Family

Sources: Khavinson VK, Bull Exp Biol Med 2001, PMID 11713572; Khavinson VKh et al., Adv Gerontol 2013, PMID 24003726.

Approval, Market and Regulatory Reality

In Russia, Vilon holds the status of a peptide bioregulator drug and is used clinically as an immunomodulator and anti-aging adjuvant. In the EU (EMA), the USA (FDA), Germany (BfArM), Switzerland (Swissmedic) and Canada (Health Canada) Vilon is not approved.

Why no Western approval? The reasons are structural:

• Patentability: Lys-Glu is a nature-identical dipeptide – no defensible New Chemical Entity patent position. Western pharmaceutical investors avoid such molecules.
• Standardisation: peptide bioregulators are developed in academic institutes, not in GMP-conformant pharmaceutical pipelines. FDA/EMA-conformant cGMP production would be the first step – a step that has never been taken.
• Evidence standard: Western regulators require Phase 3 RCTs under GCP standards. The existing Vilon studies are small, often open-label, and predominantly published in Russian-language journals.
• Language barrier: primary publications are mostly in Russian; methodological details are difficult to access for Western reviewers.

Important: "Research-grade" peptides from online suppliers are not a therapeutic alternative. Purity, sterility, dosing accuracy and pharmaceutical quality are not guaranteed. The trade in unapproved peptide medicines is a criminal offence in Germany under § 95 of the German Medicines Act (Arzneimittelgesetz, AMG).

Side Effects and Safety Profile

From the available data, Vilon's safety profile can be summarised as follows:

• Acute toxicity: in published studies, no reports of serious adverse events (SAEs). Subcutaneous, intramuscular and oral administration in rats and mice over months was tolerated without chronic toxicity signals.
• Mutagenicity: in the available studies, no evidence of mutagenic activity.
• Immunogenicity: as a two-amino-acid peptide, theoretically non-immunogenic – peptides below ~8 amino acids generally do not elicit an antibody response.
• Clinical observation (Kuznik 2007): in elderly type-1 diabetics, no serious adverse events were reported. The observed effects (improved coagulation, reduced insulin dose) were therapeutically desirable.
• Theoretical caution: as a thymic immunomodulator, Vilon could in theory trigger autoimmune processes – not systematically investigated in published studies.

Overall, the safety profile – to the extent that it can be assessed – is favourable. The data base, however, is not large enough to safely exclude rare adverse events.

Practical Implications for Longevity

Even though Vilon is not available in Germany or the wider West, the biological processes Vilon addresses are worth considering:

1. Thymic involution: from about the age of 35, thymic involution begins. Vilons's direct mitogenic effect on thymocytes (PMID 15455093) targets exactly this process.
2. Immune surveillance: Vilon's bladder-cancer reduction in the rat model (PMID 11586406) is consistent with this hypothesis – the negative HER-2/neu finding (PMID 12209581) shows, however, that the effect is context-dependent.
3. Chromatin epigenetics: Vilon's deheterochromatinisation of ribosomal genes in lymphocytes of 75-88-year-olds (PMID 15105581, 37042594) intervenes directly in the epigenetic axis of the hallmarks of aging. The SIRT1 mechanism (PMID 37782636) connects Vilon to NAD⁺/sirtuin metabolism.
4. Aging gut mucosa: Vilon's trophic effect (maltase↑, alkaline phosphatase↑, PMID 12660839) is relevant to malabsorption and "leaky gut" in old age.

What Vilon is not: a metabolic peptide, a GLP-1 agonist, an appetite suppressant, a direct mTOR inhibitor. Vilon addresses the immunological and epigenetic axes of aging.

Scientific Limitations and Critique

Vilon is a fascinating peptide. An honest discussion requires a clear-eyed view of the structural weaknesses in the evidence base:

• Publication and funding bias: the overwhelming majority of Vilon data – preclinical and clinical – originates from the St Petersburg Institute of Bioregulation and Gerontology (Khavinson et al.) and its Georgian collaboration partners (Lezhava et al.). Independent Western replications of these findings remain limited – a textbook confirmation-bias setting.
• No Western Phase 2/3 RCTs: Vilon has never been tested in a Western, GCP-conformant, multicentre Phase 2/3 study. The clinical data (Kuznik 2007, PMID 18306698) are small, open-label, and methodologically below Western standards.
• 2023 mechanism not independently replicated: the SIRT1/PARP1/PARP2 and GCGG-binding data (PMID 37782636) come exclusively from the Khavinson group. The in silico DNA-binding hypothesis is not yet experimentally validated by direct binding assays (ChIP, EMSA, ChIP-seq).
• Language and disciplinary barrier: primary publications are predominantly in Russian; methodological details are difficult for Western reviewers to verify.
• Commercial disinterest spiral: Vilon is not patentable as a new chemical entity → no Western pharma investment → no Phase 3 → no approval → no replication.
• No hard endpoint: the clinical data show surrogate parameters (coagulation markers, T-cell subsets, insulin dose) – not mortality, cancer incidence or hospitalisation.

This is not a fundamental critique of the experimental findings – the data are consistent and biologically plausible. It is a structural critique of the generalisability: as long as independent replication is missing, Vilon remains a fascinating research molecule – not a clinical standard.

Outlook: What Would the Next Steps Look Like?

Vilon will not enter Western guidelines in the foreseeable future. But the scientific questions deserve answers:

• Independent replication of the SIRT1/PARP data: an external research group would need to replicate the Khavinson 2023 findings – ideally with a direct DNA-binding assay (ChIP-seq for GCGG).
• Modern pharmacokinetics: oral bioavailability, half-life, volume of distribution, metabolites – none of these have been properly published. LC-MS/MS studies in humans would be the first step.
• Combination studies: Vilon + Epithalon, Vilon + Cortagen – the theoretical rationale exists; clinical testing is absent.
• Senolytic cross-testing: Vilon's chromatin effects are conceptually related to senolytic approaches. A direct comparison in senescence models would be interesting.

Subjective opinion: Vilon is one of the most fascinating Russian peptide bioregulators – small (274 Da, pharmacologically almost nothing), old (documented since the 1990s), independent (no Western pharma sponsor), and at the same time astonishingly under-researched in the West. The 2023 mechanistic finding is methodologically solid and biologically exciting. Until independent replication is available, Vilon remains an interesting research molecule from an aging pharmacological tradition – no more, no less.

Sources